Page 19 - Expanded Access News Today

Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA USA - English Share this article Share this article CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression...

Secondary Mktg., AE Jobs; Workflow, Payment, Doc Tools; Company Sponsored Events; VA and FHA Updates Apr 27 2021, 8:18AM When I was a kid, I did things like eat Wonder Bread. I still enjoy a McDonald’s cheeseburger on occasion. As a kid I remember sharing a Coke with the kids on my street between hoops games, having a bite of a buddy’s cookie, or merely rinsing off a scratch with hose water. Now there are some that tell you you’ll die from doing any of those. Th...

email article Biogen will launch an expanded access program for its investigational amyotrophic lateral sclerosis (ALS) drug tofersen in July -- but thats likely too late for the patient whose quest to try the therapy has brought it into the spotlight. In a "community update" posted to its website, Biogen said it will offer compassionate use to the "most rapidly progressing patients" starting in mid-July, once placebo patients in its phase III trial are transitioned to active therapy. T...

Vitro Diagnostics, Inc.: Vitro Biopharma Inc. January 31st 2021, 1st Quarter ended Financial Results of Operations and Shareholder Letter st, 2021, financial results of operations. Vitro Biopharma recorded quarter ended January 31 st, 2021 revenues of $ 127,492 vs $225,921 a decrease of 44% over the prior comparative quarter directly attributed to the COVID-19 pandemic. Revenues in the first quarter of 2021 of $127,492 were down 21% over the $161,888 recorded in the prior fourth quarter. The de...

The Worldwide Virtual Clinical Trials Industry is Expected to Reach $10 Billion by 2026 News provided by Share this article Share this article ResearchAndMarkets.coms offering. The Global Virtual Clinical Trials Market size is expected to reach $10 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period. Virtual Clinical Trials (VCTs) are also known as remote or decentralized trails, are a comparatively new but still underused technique of carrying out clinical resea...

Resilience Continues Expansion With Acquisition Of Biologics Manufacturing Company Ology Bioservices SAN DIEGO & BOSTON--(BUSINESS WIRE)-- Resilience (National Resilience, Inc.), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced it has acquired Ology Bioservices, Inc., (Ology Bio) a privately held company that also specializes in biologic drug substance manufacturing from early stage through commercial products. Ology Bio, based in Alachua, Flor...

Arguments for and against no-excuse absentee/mail-in voting Kevin Kosar, Marc Hyden and Steven Greenhut ( R Street): “Voting absentee or by mail is a safe, trusted and age-old practice. Moreover, expanded access to absentee voting comports with conservative principles, which helps explain why a number of conservative state policymakers have advanced proposals to achieve it. Finally, and critically, policymakers should take note that polling data indicate very clearly that the public strongl...

Share this article SAN FRANCISCO, April 13, 2021 /PRNewswire/ -- The global virtual clinical trials market size is expected to reach USD 11.5 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected  to expand at a CAGR of 5.7% from 2021 to 2028. The need for patient diversity clubbed with enhanced data collection in clinical trials is boosting virtual/decentralized clinical trials (DCTs) market growth. Key suggestions from the report: The oncology segm...

Resilience Acquires Ology Bioservices Share Resilience (National Resilience), a biomanufacturing company, acquired Ology Bioservices (Ology Bio), a privately held company that reportedly also specializes in biologic drug substance manufacturing from early stage through commercial products. Ology Bio, based in Alachua, FL, develops and manufactures drugs and biologics for commercial customers as well as the US government, with more than $1.8 billion in government contracts awarded. The acquisiti...

(1) Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is over 75% enrolled, with completion of enrollment expected in the coming weeks Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involv...